Screener
Odyssey Therapeutics ODTX Cash & Equivalents
Cash & Equivalents at other companies
Other financials
Where this comes from
Reported directly by Odyssey Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue.
The source filing: Odyssey Therapeutics’s 10-Q, filed August 6, 2026. Open the filing →
- Filed
- Aug 5, 2026, 8:00 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-335822
FAQ
- What is Odyssey Therapeutics's cash & equivalents?
- Odyssey Therapeutics (ODTX) reported cash & equivalents of $82.03M in Q2 2026.
- How has Odyssey Therapeutics's cash & equivalents changed year-over-year?
- Odyssey Therapeutics's cash & equivalents decreased by 49.7% year-over-year, from $163M to $82.03M.
- What does cash & equivalents mean?
- Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.
Ask your AI about Odyssey Therapeutics's cash & equivalents.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude